Stem Cell Therapy in Mental Retardation

Status

Withdrawn

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02245724

Enrollment

Registered

2014-09-22

Start date

2011-09-30

Completion date

2016-09-30

Last updated

2018-10-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mental Retardation

Keywords

Mental retardation, Autologous mononuclear cell therapy, Stem cell

Brief summary

The purpose of this study was to analyze the benefit of autologous mononuclear cell therapy in mental retardation.

Interventions

BIOLOGICALStem Cell

Autologous bone marrow mononuclear cell transplantation

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

6 Months to 40 Years

Healthy volunteers

Inclusion criteria

* diagnosed cases of mental retardation * age above 6 months

Exclusion criteria

* presence of acute infections such as Human immunodeficiency virus/Hepatitis B Virus/Hepatitis C Virus * malignancies * bleeding tendencies * pneumonia * renal failure * severe liver dysfunction * severe anemia \[Hemoglobin \< 8\] * any bone marrow disorder * space occupying lesion in brain * other acute medical conditions such as respiratory infection and pyrexia

Design outcomes

Primary

Measure	Time frame	Description
Change in common clinical symptoms of mental retardation	1 year	Change in symptoms such as cognition, remote memory, problem solving,understanding of relationships,social interaction,communication,self care, activities of daily living will be recorded at 1 year follow up.

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 7, 2026